myrawtruth.com
MyRawTruth.com is an AbbVie drug-marketing site that compares RINVOQ with DUPIXENT for moderate-to-severe eczema.
What is MyRawTruth.com?
The domain opens an official RINVOQ page about a head-to-head study of two prescription eczema treatments (MyRawTruth.com).
The page is made for people aged 12 and older whose eczema has not improved enough with earlier treatment.
Its main message is that RINVOQ may reduce itching and clear skin faster than DUPIXENT for some patients.
The name “My Raw Truth” sounds like a patient support project, but the live page is a branded medicine advertisement.
AbbVie makes RINVOQ, pays for the website, and owns the marketing message.
This link between the maker and the site appears in the footer, along with AbbVie’s copyright, privacy notice, and legal terms.
What does the website claim?
The page highlights one study of 920 people between 12 and 64 years old.
It says more than twice as many people taking RINVOQ reached both “little to no itch” and “90% clearer skin” after 16 weeks when compared with people taking DUPIXENT.
It also presents separate results for itch relief and skin clearance after four and 16 weeks.
The study behind these claims is called LEVEL UP and is registered as NCT05601882 (ClinicalTrials.gov).
The study compared oral upadacitinib, sold as RINVOQ, with injected dupilumab, sold as DUPIXENT.
Patients knew which drug they received, so their knowledge may have affected reports about symptoms such as itching.
The website states this limit, but the large result graphics are much easier to notice than the smaller study warning.
Does the comparison tell the whole story?
No single trial can show which treatment is best for every person.
The RINVOQ group began with 15 milligrams once a day, but some patients moved to 30 milligrams if they did not respond enough.
That detail matters because the higher dose can change both the chance of improvement and the chance of side effects.
The study was also not designed to make a full safety comparison.
RINVOQ and DUPIXENT work in different ways, serve partly different groups, and carry different risks.
This means the large “more than twice as many” message should not be read as proof that RINVOQ is always the better choice.
How are RINVOQ and DUPIXENT different?
RINVOQ is a pill taken once a day, while DUPIXENT is an injection given at set times.
RINVOQ is approved for certain people aged 12 and older whose eczema did not respond to earlier treatment or cannot be managed well with other pills or injections (FDA RINVOQ label).
DUPIXENT is approved for adults and children aged six months and older whose moderate-to-severe eczema is not controlled well by prescription skin treatments or who cannot use those treatments (FDA DUPIXENT label).
These approval rules are not the same, so a direct result from one selected study group may not apply to every person who can receive either drug.
The drugs also differ in dosing, health checks, lab monitoring, insurance rules, and likely out-of-pocket cost.
What safety facts deserve close attention?
RINVOQ carries an FDA boxed warning, which is the agency’s strongest warning format.
Its listed serious risks include severe infections, cancer, blood clots, major heart events, and a higher risk of death in certain older adults with heart risk factors.
Doctors may need to test for tuberculosis, check blood counts, review liver health, and discuss vaccines before or during treatment.
DUPIXENT does not carry a boxed warning, but it can still cause serious allergic reactions, eye problems, blood-vessel inflammation, psoriasis, and joint pain.
The absence of a boxed warning does not mean a drug has no risks, just as stronger study results do not erase RINVOQ’s risks.
A doctor must weigh skin symptoms, age, smoking history, infection risk, heart health, other medicines, and treatment goals.
Is MyRawTruth.com trustworthy?
The site is legitimate in the sense that it identifies AbbVie, provides prescribing information, includes safety language, and links to tools for speaking with a doctor.
Its study claims can be checked against a registered clinical trial.
However, it is still a sales page from the company that benefits when doctors prescribe RINVOQ.
The page selects facts that support its product, uses bold visual comparisons, and places the most serious limits farther from the main headline.
A useful reading rule is to treat the site as one company’s evidence summary, not as neutral medical advice.
What should a visitor do next?
Write down the result that interests you, then ask a dermatologist whether that exact result applies to your age, health history, and past treatment.
Ask about both benefits and harms at the approved starting dose.
Also ask what happens if the first dose does not work, how long treatment may last, and which tests are needed.
MyRawTruth.com can help start that talk, but it should never make the treatment choice for you.